Global Expansion Bora Pharmaceuticals is rapidly expanding its footprint, led by the acquisition of MacroGenics assets and new facilities in Maryland, Rockville, and Frederick, signaling growth in biologics manufacturing capacity that could support multi-region CDMO partnerships.

Biologics Capability Strategic investments in biologics manufacturing and 11,000-liter scale facilities position Bora as a strong partner for biologics drug substance and fill/finish needs, presenting opportunities with biopharma companies seeking scalable GMP production.

Awarded Prestige Recognition as TIME World's Most Impactful Companies and Life Sciences Company of the Year enhances Bora’s credibility with potential customers seeking proven, high-profile CDMOs for complex programs.

End-to-End CDMO Bora offers full-spectrum services from early-phase clinical development to commercial manufacturing and packaging across multiple dosage forms, enabling potential clients to consolidate development and manufacturing with a single vendor.

Strategic Partnerships Existing and emerging partnerships, including acquisitions and facility expansions, indicate a collaborative growth approach that can appeal to companies looking for integrated supply chain resilience and scalable capacity across regions.